Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments.
Humans
Stomach Neoplasms
/ pathology
Peritoneal Neoplasms
/ drug therapy
Combined Modality Therapy
Retrospective Studies
Chemotherapy, Cancer, Regional Perfusion
Cytoreduction Surgical Procedures
Postoperative Complications
/ therapy
Hyperthermia, Induced
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Survival Rate
Cytoreductive surgery
Gastric cancer
Hyperthermic intraperitoneal chemotherapy (HIPEC)
Oligometastatic gastric cancer
Peritoneal metastasis
Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
received:
07
08
2023
accepted:
23
10
2023
medline:
20
11
2023
pubmed:
17
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
Gastric cancer with peritoneal metastasis (GCPM) has an unfavourable prognosis. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are promising treatment options that have been shown to improve survival. The aim of this study was to assess the impact of different treatments such as systemic chemotherapy, systemic chemotherapy + PIPAC, and CRS + HIPEC in patients with GCPM. This single-centre retrospective study included 82 patients with GCPM treated between January 2016 and June 2021. After first-line chemotherapy, depending on disease response and burden, the patients were divided into three treatment groups: chemotherapy alone, chemotherapy + PIPAC, and CRS + HIPEC. The primary outcome was overall survival (OS) from diagnosis, which was compared among the treatment groups. Thirty-seven (45.1%) patients were administered systemic chemotherapy alone, 25 (30.4%) received chemotherapy + PIPAC, and 20 (24.4%) underwent CRS + HIPEC. The CRS + HIPEC group had better OS (median 24 months) than the PIPAC group (15 months, p = 0.01) and chemotherapy group (5 months, p = 0.0001). Following CRS + HIPEC, the postoperative grade 3-4 complication rate was 25%, and no postoperative in-hospital deaths occurred. The median disease-free survival (DFS) was 12 months. Multivariate analysis identified peritoneal carcinomatosis index (PCI) > 7 as an independent predictor of worse DFS. No independent predictors of OS were identified. Among patients with GCPM, we identified a highly selected population with oligometastatic disease. In this group, CRS + HIPEC provided a significant survival advantage with an acceptable major complication rate compared with other available therapies (systemic chemotherapy alone or in combination with PIPAC).
Identifiants
pubmed: 37973620
doi: 10.1007/s00423-023-03163-1
pii: 10.1007/s00423-023-03163-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Canadian Cancer Statistics Advisory Committee (2019) Canadian cancer statistics 2019. Canadian Cancer Society, Toronto, ON. Available at: https://www.cancer.ca/Canadian-Cancer-Statistics-2019-EN . Accessed 30 Nov 2022
Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, Ajani J, Badgwell BD (2017) Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol 24:2679–2687. https://doi.org/10.1245/S10434-017-5838-Y/FIGURES/2
doi: 10.1245/S10434-017-5838-Y/FIGURES/2
pubmed: 28332034
Seshadri RA, Glehen O (2016) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 22:1114. https://doi.org/10.3748/WJG.V22.I3.1114
doi: 10.3748/WJG.V22.I3.1114
pubmed: 26811651
pmcid: 4716024
Polom K, Marano L, Roviello G, Petrioli R, Piagnerelli R, De Franco L, Marrelli D, Roviello F (2016) International Journal of Hyperthermia Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: from treating the incurable to preventing recurrence Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: from treating the incurable to preventing recurrence. Int J Hyperth 32:173–179. https://doi.org/10.3109/02656736.2015.1111432
doi: 10.3109/02656736.2015.1111432
Badgwell B, Ikoma N, Murphy MB, Wang X, Estrella J, Roy-Chowdhuri S, Das P, Minsky BD, Lano E, Song S, Mansfield P, Ajani J, Surg A (2020) A Phase II Trial of Cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Oncol 18:258–264. https://doi.org/10.1245/s10434-020-08739-5
doi: 10.1245/s10434-020-08739-5
Badgwell B (2022) Regional therapy trials in peritoneal metastases: the path to standardization of care for gastric cancer. J Surg Oncol 125:64–68. https://doi.org/10.1002/JSO.26718
doi: 10.1002/JSO.26718
pubmed: 34897716
Thomassen I, Van Gestel YR, Van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, De Hingh IH (2014) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134:622–628. https://doi.org/10.1002/IJC.28373
doi: 10.1002/IJC.28373
pubmed: 23832847
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442. https://doi.org/10.1200/JCO.2007.13.9378
doi: 10.1200/JCO.2007.13.9378
pubmed: 18349393
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X
doi: 10.1016/S0140-6736(10)61121-X
pubmed: 20728210
Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I (2014) Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol 110:275–284. https://doi.org/10.1002/jso.23633
doi: 10.1002/jso.23633
pubmed: 25042700
pmcid: 6301031
Marano L, Marrelli D, Sammartino P, Biacchi D, Graziosi L, Marino E, Coccolini F, Fugazzola P, Valle M, Federici O, Baratti D, Deraco M, Di Giorgio A, Macrı` A, Pasqual EM, Framarini M, Vaira M, Roviello F, Marano L (2021) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter study of “Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.” Ann Surg Oncol. https://doi.org/10.1245/s10434-021-10157-0
doi: 10.1245/s10434-021-10157-0
pubmed: 34057569
pmcid: 8590997
Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, Bereder J-M, Abboud K, Fréd´ F, Marchal F, Quenet F, Goere D, Msika S, Arvieux C, Pirro N, Wernert R, Rat P, Gagnì J, Lefevre JH, Courvoisier T, Kianmanesh R, Vaudoyer D, Rivoire M, Meeus P, Passot G, Glehen O (2019) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 37:2028–2040
doi: 10.1200/JCO.18.01688
pubmed: 31084544
Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtröder C, Schüle S, Schlitt HJ, Roitman M, Tepel J, Sulkowski U, Uzunoglu F, Hünerbein M, Hörbelt R, Ströhlein M, Beckert S, Königsrainer I, Königsrainer A (2020) Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer 23:11–22. https://doi.org/10.1007/S10120-019-00978-0/FIGURES/4
doi: 10.1007/S10120-019-00978-0/FIGURES/4
pubmed: 31228044
Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17:2370–2377. https://doi.org/10.1245/S10434-010-1039-7
doi: 10.1245/S10434-010-1039-7
pubmed: 20336386
Yang X-J, Huang C-Q, Suo T, Mei L-J, Yang G-L, Cheng F-L, Zhou Y-F, Xiong B, Yonemura Y, Li Y (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581. https://doi.org/10.1245/s10434-011-1631-5
Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, Bakrin N, Kepenekian V, Glehen O (2021) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol 47:123–127. https://doi.org/10.1016/J.EJSO.2020.05.021
doi: 10.1016/J.EJSO.2020.05.021
pubmed: 32561204
Sindayigaya R, Dogan C, Demtröder CR, Fischer B, Karam E, Buggisch JR, Tempfer CB, Lecomte T, Ouaissi M, Giger-Pabst U (2021) Clinical outcome for patients managed with low-dose cisplatin and doxorubicin delivered as pressurized intraperitoneal aerosol chemotherapy for unresectable peritoneal metastases of gastric cancer. Ann Surg Oncol 29:112–123. https://doi.org/10.1245/S10434-021-10860-Y/TABLES/4
doi: 10.1245/S10434-021-10860-Y/TABLES/4
pubmed: 34611790
Di Giorgio A, Macrì A, Ferracci F, Robella M, Visaloco M, De Manzoni G, Sammartino P, Sommariva A, Biacchi D, Roviello F, Pastorino R, Pires Marafon D, Rotolo S, Casella F, Vaira M (2023) 10 Years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis. Cancers (Basel) 15(4):1125. https://doi.org/10.3390/CANCERS15041125
Case A, Prosser S, Peters CJ, Adams R, Gwynne S (2022) Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: a systematic review by the PIPAC UK collaborative. Crit Rev Oncol Hematol 180:103846. https://doi.org/10.1016/J.CRITREVONC.2022.103846
Di Giorgio A, Santullo F, Attalla El Halabieh M, Lodoli C, Abatini C, Alessandra Calegari M, Martini M, Rotolo S, Pacelli F (2021) Clinical and molecular features in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from colorectal cancer. Gastrointest Surg 25(10):2649–2659. https://doi.org/10.1007/s11605-021-05073-3/Published
Santullo F, Pacelli F, Abatini C, Attalla El Halabieh M, Fortunato G, Lodoli C, Giovinazzo F, Rotolo S, Di Giorgio A (2021) Cytoreduction and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin: a single center experience. Front Surg 8:715119. https://doi.org/10.3389/FSURG.2021.715119
Santullo F, Abatini C, Attalla El Halabieh M, Ferracci F, Lodoli C, Barberis L, Giovinazzo F, Di Giorgio A, Pacelli F (2022) The road to technical proficiency in cytoreductive surgery for peritoneal carcinomatosis: risk-adjusted cumulative summation analysis. Front Surg 9:877970. https://doi.org/10.3389/FSURG.2022.877970/FULL
Di Giorgio A, Schena CA, El Halabieh MA, Abatini C, Vita E, Strippoli A, Inzani F, Rodolfino E, Romanò B, Pacelli F, Rotolo S (2020) Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): a bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol 34:270–275. https://doi.org/10.1016/J.SURONC.2020.05.006
doi: 10.1016/J.SURONC.2020.05.006
pubmed: 32891341
Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, Shankar LK (2009) Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer (Oxford, England : 1990) 45(2):290–299. https://doi.org/10.1016/j.ejca.2008.10.030
doi: 10.1016/j.ejca.2008.10.030
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer (Oxford, England : 1990) 62:132–137. https://doi.org/10.1016/j.ejca.2016.03.081
doi: 10.1016/j.ejca.2016.03.081
Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA (2018) A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 150:23–30. https://doi.org/10.1016/J.YGYNO.2018.05.001
doi: 10.1016/J.YGYNO.2018.05.001
pubmed: 29743140
Amin MB, Edge SB, Greene FL, Schilsky RL, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup MJ, Brierley JD, Gaspar LE, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) American Joint Committee on Cancer (AJCC). AJCC cancer staging manual, 8th edn. Springer International Publishing: American Joint Commission on Cancer
Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, De Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–196. https://doi.org/10.1097/SLA.0B013E3181B13CA2
doi: 10.1097/SLA.0B013E3181B13CA2
pubmed: 19638912
Manzanedo I, Pereira F, Caro CR, Pérez-Viejo E, Serrano Á, Calvo AG, Regueira FM, Casado-Adam Á, Cascales-Campos PA, Arteaga X, García-Fadrique A, Gómez Sanz R, García AL, Zozaya G, Arjona Á, Gil Martínez J, Manzanedo I (2019) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol 26(8):2615–2621. https://doi.org/10.1245/s10434-019-07450-4
Rau B, Lang H, Königsrainer A, Gockel I, Seeliger H (2021) 1376O the effect of hyperthermic intraperitoneal chemotherapy(HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC)with synchronous peritoneal metastasis (PM): a randomizedmulticentre phase III trial (GASTRIPEC-I-trial). Ann Oncol 32:S1040
doi: 10.1016/j.annonc.2021.08.1485
Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B (2021) Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI. Eur J Surg Oncol 47:172–180. https://doi.org/10.1016/J.EJSO.2020.10.006
doi: 10.1016/J.EJSO.2020.10.006
pubmed: 33071173
Green BL, Blumenthaler AN, Gamble LA, Mcdonald JD, Robinson K, Connolly M, Epstein M, Hernandez JM, Blakely AM, Badgwell BD, Davis JL (2023) Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials. Ann Surg Oncol. https://doi.org/10.1245/s10434-022-12761-0
doi: 10.1245/s10434-022-12761-0
pubmed: 36434483
Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:571–573. https://doi.org/10.1016/S0140-6736(00)49915-0
doi: 10.1016/S0140-6736(00)49915-0
Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S, Kwang Yang H, Ji J, Baba H, Kitagawa Y, Morita S, Nishiyama M, Kodera Y (2021) International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 6:227–240. https://doi.org/10.1002/AGS3.12515
doi: 10.1002/AGS3.12515
pubmed: 35261948
pmcid: 8889854
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17(1):893. https://doi.org/10.1186/S12885-017-3918-9
Rihuete Caro C, Manzanedo I, Pereira F, Carrion-Alvarez L, Serrano Á, Pérez-Viejo E (2018) Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol 44:1805–1810. https://doi.org/10.1016/J.EJSO.2018.06.036
doi: 10.1016/J.EJSO.2018.06.036
pubmed: 30087071
Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, Montori G, Ansaloni L (2015) Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol 41:911–919. https://doi.org/10.1016/J.EJSO.2015.03.231
doi: 10.1016/J.EJSO.2015.03.231
pubmed: 25936764
Casella F, Bencivenga M, Rosati R, Fumagalli R, Marrelli D, Pacelli F, Macrì A, Donini A, Torroni L, Pavarana M, De Manzoni G (2022) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne. Pleura Peritoneum 7(3):135–141. https://doi.org/10.1515/pp-2022-0111
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2
doi: 10.1016/S0140-6736(21)00797-2
pubmed: 34102137
pmcid: 8436782